$1.06
-0.09 (-7.83%)
Open$1.17
Previous Close$1.15
Day High$1.17
Day Low$1.02
52W High$12.80
52W Low$0.62
Volume—
Avg Volume243.1K
Market Cap7.66M
P/E Ratio—
EPS$-5.74
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,809.4% upside
Current
$1.06
$1.06
Target
$20.24
$20.24
$14.74
$20.24 avg
$23.30
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.23M | 4.47M | 3.50M |
| Net Income | -124,680 | -125,666 | -103,892 |
| Profit Margin | -3.0% | -2.8% | -3.0% |
| EBITDA | -157,557 | -149,483 | -127,277 |
| Free Cash Flow | -89,797 | -95,523 | -91,369 |
| Rev Growth | +15.0% | +2.0% | +12.9% |
| Debt/Equity | 1.05 | 1.12 | 1.09 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |